News & Blog

So You Heard About Rintega? Here’s What’s Next for Brain Tumor Drug Development

Last week, news broke that a promising clinical trial of a new type of treatment for a subset of glioblastoma (GBM) patients – an immunotherapeutic vaccine made by Celldex Therapeutics called RINTEGA (rindopepimut) – was discontinued because patients receiving the investigational therapy were not doing better than patients in the control arm. As we said in our statement regarding […]

Top Ten NBTS Blogs of 2015

2015 was a big year for brain tumor research and advocacy. Today, we’re featuring the most read blogs from 2015 that focus on breakthrough science and community stories that both raise the profile of our disease and honor those who have worked tirelessly in the fight against brain tumors; either as patients or clinicians. This […]

Survey Results: Clinical Trial Participation

  National Brain Tumor Society, in conjunction with neuro-oncologists, scientific researchers, and the biopharmaceutical industry, is constantly looking for new and better treatments for patients. However, scientific progress in a laboratory does not necessarily always lead to new treatments for patients. First, those laboratory results need to be evaluated and confirmed in high quality clinical trials to ensure […]